PM8002 in Combination With Chemotherapy as First Line Therapy in Hepatocellular Carcinoma
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-05-18
- Last Posted Date
- 2023-05-22
- Lead Sponsor
- Biotheus Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT05864105
- Locations
- 🇨🇳
Cancer Hospital of The University of Chinese Academy of Sciences, Hangzhou, Zhejiang, China
Clinical Study of PM1003 in Phase I/IIa Treatment of Advanced Malignant Solid Tumors
- First Posted Date
- 2023-05-17
- Last Posted Date
- 2023-05-17
- Lead Sponsor
- Biotheus Inc.
- Target Recruit Count
- 285
- Registration Number
- NCT05862831
- Locations
- 🇨🇳
Cancer Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China
🇨🇳Shanghai Orient Hospital, Shanghai, China
A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Biotheus Inc.
- Target Recruit Count
- 445
- Registration Number
- NCT05844150
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, China
🇨🇳The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
🇨🇳The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
Phase I/IIa Study for PM1032 in the Treatment of Patients With Advanced Solid Tumors
- First Posted Date
- 2023-05-03
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Biotheus Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT05839106
- Locations
- 🇨🇳
Shanghai Orient Hospital, Shanghai, China
🇨🇳Shulan (Hang Zhou) Hospital, Hangzhou, China
🇨🇳The first affiliated hospital of nanchang university, Nanchang, China
A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With NSCLC
Phase 2
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-03-07
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Biotheus Inc.
- Target Recruit Count
- 374
- Registration Number
- NCT05756972
- Locations
- 🇨🇳
Medical Ethics Committee of Guangdong Provincial People's Hospital, Guangzhou, Guangdonng, China
A Study of PM1009 (Anti-TIGIT/PVRIG) in Patients With Advanced Tumours
- First Posted Date
- 2022-11-07
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Biotheus Inc.
- Target Recruit Count
- 54
- Registration Number
- NCT05607563
- Locations
- 🇨🇳
Shanghai Orient Hospital, Shanghai, China
A Study of PM1021 (Anti-TIGIT) With or Without PM8001 (Anti-PD-L1/TGF-β) in Patients With Advanced Solid Tumours
- First Posted Date
- 2022-09-13
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Biotheus Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT05537051
© Copyright 2024. All Rights Reserved by MedPath